Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Published, JLR Papers in Press, May 24, 2007.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Lipid Research

• Publication date

  2007-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1194/jlr.M700108-JLR200PMID 17525476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Severe Hypertriglyceridemia in Human APOC1 Transgenic Mice is Caused by ApoCI-Induced Inhibition of LPL

  2007cited by this paper
• Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

  2007cited by this paper
• Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits

  2006cited by this paper
• The failure of torcetrapib: was it the molecule or the mechanism?

  2006cited by this paper
• Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.

  2006cited by this paper
• Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice

  2006influential reference
• Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation

  2005cited by this paper
• Lipid transfer proteins (LTP) and atherosclerosis.

  2005cited by this paper
• Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein.

  2005cited by this paper
• Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.

  2005cited by this paper
• Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet Published, JLR Papers in Press, August 16, 2005. DOI 10.1194/jlr.M500051-JLR200

  2005cited by this paper
• Rosuvastatin Reduces Plasma Lipids by Inhibiting VLDL Production and Enhancing Hepatobiliary Lipid Excretion in ApoE*3-Leiden Mice

  2005cited by this paper
• Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.

  2005cited by this paper
• Paradoxical Effects of Fenofibrate and Nicotinic Acid in Apo E-Deficient Mice

  2005influential reference
• Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M400361-JLR200

  2005influential reference
• Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400301-JLR200

  2005cited by this paper
• Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

  2005cited by this paper
• Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib

  2004cited by this paper
• Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

  2004cited by this paper
• The Peroxisome Proliferator-activated Receptor α (PPARα) Agonist Ciprofibrate Inhibits Apolipoprotein B mRNA Editing in Low Density Lipoprotein Receptor-deficient Mice

  2004cited by this paper
• Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.

  2004cited by this paper
• Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice Published, JLR Papers in Press, August 16, 2004. DOI 10.1194/jlr.M400191-JLR200

  2004cited by this paper
• Cholesterol 7&agr;-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Impairs Very-Low-Density Lipoprotein Production

  2004cited by this paper
• Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.

  2003cited by this paper
• Differential Effects of Amlodipine and Atorvastatin Treatment and Their Combination on Atherosclerosis in ApoE*3‐Leiden Transgenic Mice

  2003cited by this paper
• Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.

  2003influential reference
• Differential Effects of Scavenger Receptor BI Deficiency on Lipid Metabolism in Cells of the Arterial Wall and in the Liver*

  2003cited by this paper
• Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice*

  2003influential reference
• Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol–Lowering Effect in APOE*3-Leiden Transgenic Mice: Evidence for Antiinflammatory Effects of Rosuvastatin

  2003cited by this paper
• Clofibrate, a peroxisome-proliferator, enhances reverse cholesterol transport through cytochrome P450 activation and oxysterol generation.

  2003cited by this paper
• Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.

  2003cited by this paper
• Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study

  2002cited by this paper
• The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis.

  2002cited by this paper
• Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice*

  2002cited by this paper
• Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.

  2001cited by this paper
• Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate*

  2001influential reference
• Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression

  2001cited by this paper
• Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ

  2000cited by this paper
• Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription.

  2000cited by this paper
• Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta.

  2000cited by this paper
• Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element.

  2000cited by this paper
• PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

  2000influential reference
• CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors.

  2000influential reference
• Pros and cons of inhibiting cholesteryl ester transfer protein

  2000cited by this paper
• Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes

  1999cited by this paper
• Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice.

  1998cited by this paper
• Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice.

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.

  1998cited by this paper
• Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway*

  1997cited by this paper
• Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies

  1996cited by this paper
• Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.

  1996cited by this paper
• The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

  1996cited by this paper
• Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy.

  1996cited by this paper
• Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

  1996influential reference
• Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

  1995cited by this paper
• Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia.

  1994cited by this paper
• Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.

  1994cited by this paper
• Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

  1994cited by this paper
• Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia.

  1993cited by this paper
• Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences.

  1992cited by this paper
• Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition.

  1991cited by this paper
• Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography.

  1990cited by this paper
• Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia.

  1987cited by this paper
• Kinetic analysis using specific radioactivity data.

  1986cited by this paper
• Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species.

  1982cited by this paper
• Separation of plasma lipoproteins by density-gradient ultracentrifugation.

  1975cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper
• Purification and Characterization of a Human Plasma Cholesteryl Ester Transfer Protein *

  year unknowncited by this paper

• Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol

  2026cites this paper
• High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels

  2025cites this paper
• 2025: The year in cardiovascular disease – the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?

  2025cites this paper
• Combining In Vitro, In Vivo, and In Silico Approaches to Explore the Effect of Ceratonia siliqua and Ocimum basilicum Rich Phenolic Formula on Lipid Metabolism and Plasma Lipoprotein Oxidation in Mice Fed a High-Fat Diet: A Follow-Up Study

  2025cites this paper
• Rapid Quantification of First and Second Phase Insulin Secretion Dynamics using In vitro Platform for Improving Insulin Therapy

  2023cites this paper
• A facile synthesis of 2-(4-((4-chlorophenyl)(hydroxy)methyl) phenoxy)-2-methylpropanoic acid: Metabolite of anti-hyperlipidemic drug Fenofibrate

  2023cites this paper
• Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study.

  2021cites this paper
• Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men

  2021cites this paper
• Curcumin promotes AApoAII amyloidosis and peroxisome proliferation in mice by activating the PPARα signaling pathway

  2021cites this paper
• Effects of fenofibrate and its combination with lovastatin on the expression of genes involved in skeletal muscle atrophy, including FoxO1 and its targets.

  2021cites this paper
• Effect of polyphenol, flavonoid, and saponin fractions from Thymus atlanticus on acute and chronic hyperlipidemia in mice

  2020cites this paper
• Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.

  2020cites this paper
• Protective effect of fenofibrate against high‐fat–high‐fructose diet induced non‐obese NAFLD in rats

  2020cites this paper
• Curcumin promotes progression of AApoAII amyloidosis and peroxisome proliferation in mice by activating the PPARα signaling pathway

  2020cites this paper
• Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice

  2019cites this paper
• Biochemistry and Molecular Biology of Mechanisms of Action of Fibrates – An Overview

  2019cites this paper
• Modelling of atherosclerosis in genetically modified animals.

  2019cites this paper
• The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

  2018cites this paper
• Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings

  2018cites this paper
• Systems biology of Metabolic Syndrome development and treatment

  2018cites this paper
• Comparative study of the effect of atorvastatin and fenofibrate on high-density lipoprotein cholesterol levels in patients with type 2 diabetes

  2018cites this paper
• Forhidrol, a bioactive fraction of Phaleria macrocarpa (Scheff.) Boerl., increases reverse cholesterol transport pathway by down-regulation of cholesteryl ester transfer protein activity

  2018cites this paper
• Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.

  2018cites this paper
• Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context

  2018cites this paper
• A Role for CEACAM2 protein in Insulin Secretion, Clearance and Action

  2017cites this paper
• Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy.

  2017cites this paper
• Serum CETP concentration is not associated with measures of body fat: The NEO study.

  2016cites this paper
• Comment on “Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice” by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46–54

  2016cites this paper
• Fenofibrate Decreases Insulin Clearance and Insulin Secretion to Maintain Insulin Sensitivity*

  2016cites this paper
• SALSALATE ATTENUATES DIET INDUCED NON-ALCOHOLIC STEATOHEPATITIS BY DECREASING LIPOGENIC AND INFLAMMATORY PROCESSES

  2015cites this paper
• Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells

  2015cites this paper
• Salsalate attenuates diet induced non‐alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes

  2015cites this paper
• Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study

  2015cites this paper
• Mouse models of disturbed HDL metabolism.

  2015cites this paper
• Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials.

  2015cites this paper
• Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]

  2015cites this paper
• Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.

  2015cites this paper
• Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

  2014cites this paper
• Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

  2014cites this paper
• Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity

  2014cites this paper
• APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome

  2014cites this paper
• Salsalate Activates Brown Adipose Tissue in Mice

  2014cites this paper
• Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.

  2014cites this paper
• PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]

  2014cites this paper
• A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report.

  2014cites this paper
• Effects of chocolate supplementation on metabolic and cardiovascular parameters in ApoE3L mice fed a high-cholesterol atherogenic diet.

  2013cites this paper
• Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice—a translational model for atherosclerosis

  2013cites this paper
• Fenofibrate down-regulates the expressions of androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate cancer cell line LNCaP.

  2013cites this paper
• Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development

  2013cites this paper
• PPAR Agonist-Induced Reduction of Mcp1 in Atherosclerotic Plaques of Obese, Insulin-Resistant Mice Depends on Adiponectin-Induced Irak3 Expression

  2013cites this paper
• PlasMa cholesterYl ester transFer Protein: a BioMarker For hePatic MacroPhaGes

  2013cites this paper
• Diet-associated metabolic and vascular (dys) function

  2013cites this paper
• Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice

  2013cites this paper
• Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies

  2013cites this paper
• Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: A randomized study amongst north Indians

  2013cites this paper
• Journey Through Cholesteryl Ester Transfer Protein Inhibition: From Bench to Bedside

  2013cites this paper
• Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action

  2012cites this paper
• Mapping the diverse functions of dietary fatty acids via target gene regulation

  2012cites this paper
• Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate

  2012cites this paper
• Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway.

  2012cites this paper
• Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin

  2012cites this paper
• Fenofibrate triggers apoptosis of glioblastoma cells in vitro

  2012cites this paper
• Elevation of Plasma High-Density Lipoproteins Inhibits Development of Experimental Abdominal Aortic Aneurysms

  2012cites this paper
• Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?

  2012cites this paper
• Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Plasma CETP and Increases Apolipoprotein AI Levels Without Improving the Cholesterol Efflux Properties of HDL

  2011cites this paper
• Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.

  2011cites this paper
• Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice.

  2011cites this paper
• Plasma and Liver Lipidomics Response to an Intervention of Rimonabant in ApoE*3Leiden.CETP Transgenic Mice

  2011cites this paper
• Reduced body weight in male Tspan8-deficient mice

  2011cites this paper
• Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster

  2010cites this paper
• High Density Lipoprotein (HDL) Modulation Targets.

  2010cites this paper
• Glycine amides as PPARalpha agonists.

  2010cites this paper
• Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.

  2010cites this paper
• Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated With a Decrease in Hepatic Triglyceride Content, in Patients With Type 2 Diabetes

  2010cites this paper
• Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting

  2010cites this paper
• Selective CETP Inhibition and PPARα Agonism Increase HDL Cholesterol and Reduce LDL Cholesterol in Human ApoB100/Human CETP Transgenic Mice

  2010cites this paper
• Pioglitazone Decreases Plasma CETP Mass, Associated With A Decrease In Hepatic Triglyceride Content, In Patients With Type 2 Diabetes Mellitus Running Title: Pioglitazone Decreases Plasma CETP Mass

  2010cites this paper
• Modulation of VLDL triglyceride metabolism

  2010cites this paper
• Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice.

  2010cites this paper
• Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice*

  2010cites this paper
• CETP and Inflammation in lipid metabolism and atherosclerosis

  2010cites this paper
• The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

  2009influential citation
• Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine

  2009cites this paper
• Regulation of Bile Acid and Cholesterol Metabolism by PPARs

  2009cites this paper
• CETP antagonism versus agonism in cardiovascular prevention and plaque regression

  2009cites this paper
• Lipids in Health and Disease

  2009cites this paper
• Rôle des Peroxisome Proliferator-Activated Receptors (PPAR) dans le métabolisme lipidique

  2009cites this paper
• Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.

  2009cites this paper
• PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.

  2009cites this paper
• Pleiotropic effects of fenofibrate.

  2009cites this paper
• Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.

  2009cites this paper
• Fenofibrate: treatment of hyperlipidemia and beyond

  2008cites this paper
• Pharmacologic Management of Isolated Low High-Density Lipoprotein Syndrome

  2008cites this paper
• Peroxisome Proliferator-Activated Receptor α Agonists Regulate Cholesterol Ester Transfer Protein

  2008cites this paper
• Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin

  2008cites this paper
• Lipids in Health and Disease

  2008cites this paper
• Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice

  2008cites this paper
• Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo.

  2008cites this paper
• Review Article Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism

  year unknowncites this paper